Breast cancer risk reduction

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard & 4 others Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, John H. Ward

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years substantially decreases the future risk of breast cancer provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with tamoxifen or raloxifene use should be evaluated and discussed with each woman as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, in whom the risk of breast cancer is very high, a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk of breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.

Original languageEnglish (US)
Pages (from-to)1112-1146
Number of pages35
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2010

Fingerprint

Risk Reduction Behavior
Breast Neoplasms
Mastectomy
Tamoxifen
Clinical Trials
Ovariectomy
Women's Health
Health Personnel
Decision Making
Referral and Consultation
Mutation

Keywords

  • BCRA1
  • BCRA2
  • Breast cancer
  • Breast carcinoma
  • Chemoprevention
  • LCIS
  • NCCN clinical practice guidelines
  • NCCN guidelines
  • Prophylactic mastectomy
  • Raloxifene
  • Risk assessment
  • Risk reduction
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology

Cite this

Bevers, T. B., Armstrong, D. K., Arun, B., Carlson, R. W., Cowan, K. H., Daly, M. B., ... Ward, J. H. (2010). Breast cancer risk reduction. JNCCN Journal of the National Comprehensive Cancer Network, 8(10), 1112-1146. https://doi.org/10.6004/jnccn.2010.0083

Breast cancer risk reduction. / Bevers, Therese B.; Armstrong, Deborah K.; Arun, Banu; Carlson, Robert W.; Cowan, Kenneth H; Daly, Mary B.; Fleming, Irvin; Garber, Judy E.; Gemignani, Mary; Gradishar, William J.; Krontiras, Helen; Kulkarni, Swati; Laronga, Christine; Loftus, Loretta; MacDonald, Deborah J.; Mahoney, Martin C.; Merajver, Sofia D.; Meszoely, Ingrid; Newman, Lisa; Pritchard, Elizabeth; Seewaldt, Victoria; Sellin, Rena V.; Shapiro, Charles L.; Ward, John H.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 8, No. 10, 01.10.2010, p. 1112-1146.

Research output: Contribution to journalReview article

Bevers, TB, Armstrong, DK, Arun, B, Carlson, RW, Cowan, KH, Daly, MB, Fleming, I, Garber, JE, Gemignani, M, Gradishar, WJ, Krontiras, H, Kulkarni, S, Laronga, C, Loftus, L, MacDonald, DJ, Mahoney, MC, Merajver, SD, Meszoely, I, Newman, L, Pritchard, E, Seewaldt, V, Sellin, RV, Shapiro, CL & Ward, JH 2010, 'Breast cancer risk reduction', JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. 10, pp. 1112-1146. https://doi.org/10.6004/jnccn.2010.0083
Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB et al. Breast cancer risk reduction. JNCCN Journal of the National Comprehensive Cancer Network. 2010 Oct 1;8(10):1112-1146. https://doi.org/10.6004/jnccn.2010.0083
Bevers, Therese B. ; Armstrong, Deborah K. ; Arun, Banu ; Carlson, Robert W. ; Cowan, Kenneth H ; Daly, Mary B. ; Fleming, Irvin ; Garber, Judy E. ; Gemignani, Mary ; Gradishar, William J. ; Krontiras, Helen ; Kulkarni, Swati ; Laronga, Christine ; Loftus, Loretta ; MacDonald, Deborah J. ; Mahoney, Martin C. ; Merajver, Sofia D. ; Meszoely, Ingrid ; Newman, Lisa ; Pritchard, Elizabeth ; Seewaldt, Victoria ; Sellin, Rena V. ; Shapiro, Charles L. ; Ward, John H. / Breast cancer risk reduction. In: JNCCN Journal of the National Comprehensive Cancer Network. 2010 ; Vol. 8, No. 10. pp. 1112-1146.
@article{b0d6b2e0f8834b288ce7e98e39c4b7ee,
title = "Breast cancer risk reduction",
abstract = "Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years substantially decreases the future risk of breast cancer provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with tamoxifen or raloxifene use should be evaluated and discussed with each woman as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, in whom the risk of breast cancer is very high, a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk of breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.",
keywords = "BCRA1, BCRA2, Breast cancer, Breast carcinoma, Chemoprevention, LCIS, NCCN clinical practice guidelines, NCCN guidelines, Prophylactic mastectomy, Raloxifene, Risk assessment, Risk reduction, Tamoxifen",
author = "Bevers, {Therese B.} and Armstrong, {Deborah K.} and Banu Arun and Carlson, {Robert W.} and Cowan, {Kenneth H} and Daly, {Mary B.} and Irvin Fleming and Garber, {Judy E.} and Mary Gemignani and Gradishar, {William J.} and Helen Krontiras and Swati Kulkarni and Christine Laronga and Loretta Loftus and MacDonald, {Deborah J.} and Mahoney, {Martin C.} and Merajver, {Sofia D.} and Ingrid Meszoely and Lisa Newman and Elizabeth Pritchard and Victoria Seewaldt and Sellin, {Rena V.} and Shapiro, {Charles L.} and Ward, {John H.}",
year = "2010",
month = "10",
day = "1",
doi = "10.6004/jnccn.2010.0083",
language = "English (US)",
volume = "8",
pages = "1112--1146",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "10",

}

TY - JOUR

T1 - Breast cancer risk reduction

AU - Bevers, Therese B.

AU - Armstrong, Deborah K.

AU - Arun, Banu

AU - Carlson, Robert W.

AU - Cowan, Kenneth H

AU - Daly, Mary B.

AU - Fleming, Irvin

AU - Garber, Judy E.

AU - Gemignani, Mary

AU - Gradishar, William J.

AU - Krontiras, Helen

AU - Kulkarni, Swati

AU - Laronga, Christine

AU - Loftus, Loretta

AU - MacDonald, Deborah J.

AU - Mahoney, Martin C.

AU - Merajver, Sofia D.

AU - Meszoely, Ingrid

AU - Newman, Lisa

AU - Pritchard, Elizabeth

AU - Seewaldt, Victoria

AU - Sellin, Rena V.

AU - Shapiro, Charles L.

AU - Ward, John H.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years substantially decreases the future risk of breast cancer provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with tamoxifen or raloxifene use should be evaluated and discussed with each woman as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, in whom the risk of breast cancer is very high, a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk of breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.

AB - Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years substantially decreases the future risk of breast cancer provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with tamoxifen or raloxifene use should be evaluated and discussed with each woman as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, in whom the risk of breast cancer is very high, a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk of breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.

KW - BCRA1

KW - BCRA2

KW - Breast cancer

KW - Breast carcinoma

KW - Chemoprevention

KW - LCIS

KW - NCCN clinical practice guidelines

KW - NCCN guidelines

KW - Prophylactic mastectomy

KW - Raloxifene

KW - Risk assessment

KW - Risk reduction

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=78951487384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78951487384&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2010.0083

DO - 10.6004/jnccn.2010.0083

M3 - Review article

VL - 8

SP - 1112

EP - 1146

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 10

ER -